Review of CBD liver toxicity mechanisms and drug interaction risks

CBD causes dose-dependent hepatocellular toxicity at therapeutic doses. Risk is increased with valproate co-administration through an unknown mechanism. CBD metabolism involves CYP3A4 and CYP2C19, creating significant drug interaction potential. Current pharmacokinetic models and in vitro liver models have limitations in predicting CBD safety.

Narrative review of pharmacokinetic modeling approaches, in vitro liver models, and evidence on CBD-induced hepatotoxicity mechanisms, focusing on FDA-approved Epidiolex for pediatric epilepsy.

CBD is increasingly popular as both an FDA-approved drug and consumer product, but its liver toxicity potential is underappreciated. The drug interaction with valproate is particularly concerning since many epilepsy patients take both medications.

The gap between CBD's image as a safe natural product and its documented liver toxicity at therapeutic doses highlights the need for public education. Consumer CBD products, while often lower-dose, may still pose risks for people with liver conditions or taking hepatotoxic medications.

Review focused on FDA-approved Epidiolex doses, which are higher than most consumer products. Mechanisms of hepatotoxicity not fully understood. In vitro models may not predict in vivo toxicity accurately. Consumer CBD product quality and dosing are highly variable.